of previous year which a net loss of Baht 14.65 million, the loss decrease Baht 8.37 million or decrease by 57.14% , the main reasons are as follow 1. Revenue from sale , Other income The company had

ที่ - Translation - PorBor.076 / 2017 November 14, 2017 Subject: Clarification of operating results change from the same period last year by more than 20% To: President The Stock Exchange of Thailand

Baht 894.03 million. The Company would like to clarify a significance change of Group’s operation results were summarized as follows 1. Revenue from sales of goods and rendering of services for the year

in Q2/2017. (Unit: Thousand Baht) Revenues Gross Profit Selling Admin Net(loss) profit Q2/17 222,225 80,232 19,957 22,698 (293,091)*** Q2/18 221,202 78,238 21,637 19,916 35,335 Change -1,023 -1,994

due to; Highlights: 1st quarter of FY 2020 Operating results 1st quarter 1st quarter 4th quarter % Change FY 2020 FY 2019 FY 2019 (YoY) (QoQ) Revenue from sales and services 1,828 100% 1,866 100% 2,269

results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech

2022. 4) Improved SG&A in terms of % to revenue. 2) Profit & Loss Analysis : 12 Months (Unit : Million Baht unless otherwise stated) 2022 2021 Change Amount % Change Total Revenues 28,348.1 20,967.2

2022 Change Amount % Change Total Revenues 7,354 6,345 1,009 15.9% Sales and service income 7,153 6,145 1,008 16.4% Gains on exchange rate 111 129 -18 -13.9% Other income 90 71 19 26.8% Cost of sales and

of June 30th, 2024, which can be summarized as follows: 1) Profit & Loss Analysis : Q2 2024 (3 Months) (Unit : Million Baht unless otherwise stated) Q2 2024 Q2 2023 Change Amount % Change Total

following details. Financial performance Statement of income Consolidated financial statements for the year 2018 2017 Change (Audited) (Audited/Restated) Increase (Decrease) THB Million % THB Million % THB